Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma

Mogamulizumab, a defucosylated humanized monoclonal antibody against C –C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizuma b could increase graft-versus-host disease, resulting in poor survival outcome in allogenic stem cell transplant (allo-SCT) setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research